Department of Cosmetic Science and Technology, Seowon University, Cheongju 28674, Republic of Korea.
College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National University, Daegu 41566, Republic of Korea.
J Asian Nat Prod Res. 2021 Feb;23(2):189-203. doi: 10.1080/10286020.2019.1711066. Epub 2020 Jan 24.
Aloin is the major anthraquinone glycoside obtained from the species. Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix protein and released by primary human umbilical vein endothelial cells (HUVECs) and functions as a mediator of experimental sepsis. We hypothesized that aloin could reduce TGFBIp-mediated severe inflammatory responses in HUVECs and mice. Aloin effectively inhibited lipopolysaccharide (LPS)-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. Aloin suppressed TGFBIp-induced sepsis lethality and pulmonary injury. Therefore, aloin is a potential therapeutic agent for various severe vascular inflammatory diseases, with inhibition of the TGFBIp signaling pathway as the mechanism of action. [Formula: see text].
芦荟苷是从芦荟中提取的主要蒽醌糖苷。转化生长因子-β诱导蛋白（TGFBIp）是一种细胞外基质蛋白，由原代人脐静脉内皮细胞（HUVEC）释放，作为实验性脓毒症的介质。我们假设芦荟苷可以减轻 HUVEC 和小鼠中 TGFBIp 介导的严重炎症反应。芦荟苷能有效抑制脂多糖（LPS）诱导的 TGFBIp 释放，并抑制 TGFBIp 介导的脓毒症反应。芦荟苷抑制 TGFBIp 诱导的脓毒症致死率和肺损伤。因此，芦荟苷是一种治疗各种严重血管炎症性疾病的潜在药物，其作用机制为抑制 TGFBIp 信号通路。[公式：见正文]。
